Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep;194(9):e63646.
doi: 10.1002/ajmg.a.63646. Epub 2024 May 3.

Clinical utility of comprehensive gene panel testing for common and rare causes of skeletal dysplasia and other skeletal disorders: Results from the largest cohort to date

Gretchen MacCarrick  1 , Swaroop Aradhya  2 , Mitch Bailey  3 , Dorna Chu  3 , Abigail Hunt  3 , Emanuela Izzo  3 , Deborah Krakow  4 , William Mackenzie  5 , Sarah Poll  2 , Cathleen Raggio  6 , Renée Shediac  3 , Klane K White  7 , Heather M McLaughlin  2 , Guillermo Seratti  3
Affiliations

Clinical utility of comprehensive gene panel testing for common and rare causes of skeletal dysplasia and other skeletal disorders: Results from the largest cohort to date

Gretchen MacCarrick et al. Am J Med Genet A. 2024 Sep.

Abstract

Molecular genetics enables more precise diagnoses of skeletal dysplasia and other skeletal disorders (SDs). We investigated the clinical utility of multigene panel testing for 5011 unrelated individuals with SD in the United States (December 2019-April 2022). Median (range) age was 8 (0-90) years, 70.5% had short stature and/or disproportionate growth, 27.4% had a positive molecular diagnosis (MDx), and 30 individuals received two MDx. Genes most commonly contributing to MDx were FGFR3 (16.9%), ALPL (13.0%), and COL1A1 (10.3%). Most of the 112 genes associated with ≥1 MDx were primarily involved in signal transduction (n = 35), metabolism (n = 23), or extracellular matrix organization (n = 17). There were implications associated with specific care/treatment options for 84.4% (1158/1372) of MDx-positive individuals; >50% were linked to conditions with targeted therapy approved or in clinical development, including osteogenesis imperfecta, achondroplasia, hypophosphatasia, and mucopolysaccharidosis. Forty individuals with initially inconclusive results became MDx-positive following family testing. Follow-up mucopolysaccharidosis enzyme activity testing was positive in 14 individuals (10 of these were not MDx-positive). Our findings showed that inclusion of metabolic genes associated with SD increased the clinical utility of a gene panel and confirmed that integrated use of comprehensive gene panel testing with orthogonal testing reduced the burden of inconclusive results.

Keywords: gene panel; genetic diagnostics; genetic testing; osteochondrodysplasias; skeletal disorders; skeletal dysplasia.

PubMed Disclaimer

References

REFERENCES

    1. Almeida, L. S., Pereira, C., Aanicai, R., Schröder, S., Bochinski, T., Kaune, A., Urzi, A., Spohr, T., Viceconte, N., Oppermann, S., Alasel, M., Ebadat, S., Iftikhar, S., Jasinge, E., Elsayed, S. M., Tomoum, H., Marzouk, I., Jalan, A. B., Cerkauskaite, A., & Bauer, P. (2022). An integrated multiomic approach as an excellent tool for the diagnosis of metabolic diseases: Our first 3720 patients. European Journal of Human Genetics, 30(9), 1029–1035. https://doi.org/10.1038/s41431-022-01119-5
    1. Barat‐Houari, M., Sarrabay, G., Gatinois, V., Fabre, A., Dumont, B., Genevieve, D., & Touitou, I. (2016). Mutation update for COL2A1 gene variants associated with type II collagenopathies. Human Mutation, 37(1), 7–15. https://doi.org/10.1002/humu.22915
    1. Bean, L. J. H., Funke, B., Carlston, C. M., Gannon, J. L., Kantarci, S., Krock, B. L., Zhang, S., Bayrak‐Toydemir, P., & ACMG Laboratory Quality Assurance Committee. (2020). Diagnostic gene sequencing panels: From design to report—A technical standard of the American College of Medical Genetics and Genomics (ACMG). Genetics in Medicine, 22(3), 453–461. https://doi.org/10.1038/s41436-019-0666-z
    1. Bhattacharya, K., Balasubramaniam, S., Choy, Y. S., Fietz, M., Fu, A., Jin, D. K., Kim, O. H., Kosuga, M., Kwun, Y. H., Inwood, A., Lin, H. Y., McGill, J., Mendelsohn, N. J., Okuyama, T., Samion, H., Tan, A., Tanaka, A., Thamkunanon, V., Toh, T. H., & Lin, S.‐P. (2014). Overcoming the barriers to diagnosis of Morquio a syndrome. Orphanet Journal of Rare Diseases, 9, 192. https://doi.org/10.1186/s13023-014-0192-7
    1. Bonafe, L., Cormier‐Daire, V., Hall, C., Lachman, R., Mortier, G., Mundlos, S., Nishimura, G., Sangiorgi, L., Savarirayan, R., Sillence, D., Spranger, J., Superti‐Furga, A., Warman, M., & Unger, S. (2015). Nosology and classification of genetic skeletal disorders: 2015 revision. American Journal of Medical Genetics Part A, 167(12), 2869–2892. https://doi.org/10.1002/ajmg.a.37365

Publication types

MeSH terms

Substances

LinkOut - more resources